FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2161977537> ?p ?o ?g. }

• W2161977537 endingPage "816" @default.
• W2161977537 startingPage "805" @default.
• W2161977537 abstract "BackgroundFor women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years.MethodsIn the worldwide Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, 12 894 women with early breast cancer who had completed 5 years of treatment with tamoxifen were randomly allocated to continue tamoxifen to 10 years or stop at 5 years (open control). Allocation (1:1) was by central computer, using minimisation. After entry (between 1996 and 2005), yearly follow-up forms recorded any recurrence, second cancer, hospital admission, or death. We report effects on breast cancer outcomes among the 6846 women with ER-positive disease, and side-effects among all women (with positive, negative, or unknown ER status). Long-term follow-up still continues. This study is registered, number ISRCTN19652633.FindingsAmong women with ER-positive disease, allocation to continue tamoxifen reduced the risk of breast cancer recurrence (617 recurrences in 3428 women allocated to continue vs 711 in 3418 controls, p=0·002), reduced breast cancer mortality (331 deaths vs 397 deaths, p=0·01), and reduced overall mortality (639 deaths vs 722 deaths, p=0·01). The reductions in adverse breast cancer outcomes appeared to be less extreme before than after year 10 (recurrence rate ratio [RR] 0·90 [95% CI 0·79–1·02] during years 5–9 and 0·75 [0·62–0·90] in later years; breast cancer mortality RR 0·97 [0·79–1·18] during years 5–9 and 0·71 [0·58–0·88] in later years). The cumulative risk of recurrence during years 5–14 was 21·4% for women allocated to continue versus 25·1% for controls; breast cancer mortality during years 5–14 was 12·2% for women allocated to continue versus 15·0% for controls (absolute mortality reduction 2·8%). Treatment allocation seemed to have no effect on breast cancer outcome among 1248 women with ER-negative disease, and an intermediate effect among 4800 women with unknown ER status. Among all 12 894 women, mortality without recurrence from causes other than breast cancer was little affected (688 deaths without recurrence in 6454 women allocated to continue versus 679 deaths in 6440 controls; RR 0·99 [0·89–1·10]; p=0·78). For the incidence (hospitalisation or death) rates of specific diseases, RRs were as follows: pulmonary embolus 1·87 (95% CI 1·13–3·07, p=0·01 [including 0·2% mortality in both treatment groups]), stroke 1·06 (0·83–1·36), ischaemic heart disease 0·75 (0·60–0·95, p=0·02), and endometrial cancer 1·74 (1·30–2·34, p=0·0002). The cumulative risk of endometrial cancer during years 5–14 was 3·1% (mortality 0·4%) for women allocated to continue versus 1·6% (mortality 0·2%) for controls (absolute mortality increase 0·2%).InterpretationFor women with ER-positive disease, continuing tamoxifen to 10 years rather than stopping at 5 years produces a further reduction in recurrence and mortality, particularly after year 10. These results, taken together with results from previous trials of 5 years of tamoxifen treatment versus none, suggest that 10 years of tamoxifen treatment can approximately halve breast cancer mortality during the second decade after diagnosis.FundingCancer Research UK, UK Medical Research Council, AstraZeneca UK, US Army, EU-Biomed. For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years. In the worldwide Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, 12 894 women with early breast cancer who had completed 5 years of treatment with tamoxifen were randomly allocated to continue tamoxifen to 10 years or stop at 5 years (open control). Allocation (1:1) was by central computer, using minimisation. After entry (between 1996 and 2005), yearly follow-up forms recorded any recurrence, second cancer, hospital admission, or death. We report effects on breast cancer outcomes among the 6846 women with ER-positive disease, and side-effects among all women (with positive, negative, or unknown ER status). Long-term follow-up still continues. This study is registered, number ISRCTN19652633. Among women with ER-positive disease, allocation to continue tamoxifen reduced the risk of breast cancer recurrence (617 recurrences in 3428 women allocated to continue vs 711 in 3418 controls, p=0·002), reduced breast cancer mortality (331 deaths vs 397 deaths, p=0·01), and reduced overall mortality (639 deaths vs 722 deaths, p=0·01). The reductions in adverse breast cancer outcomes appeared to be less extreme before than after year 10 (recurrence rate ratio [RR] 0·90 [95% CI 0·79–1·02] during years 5–9 and 0·75 [0·62–0·90] in later years; breast cancer mortality RR 0·97 [0·79–1·18] during years 5–9 and 0·71 [0·58–0·88] in later years). The cumulative risk of recurrence during years 5–14 was 21·4% for women allocated to continue versus 25·1% for controls; breast cancer mortality during years 5–14 was 12·2% for women allocated to continue versus 15·0% for controls (absolute mortality reduction 2·8%). Treatment allocation seemed to have no effect on breast cancer outcome among 1248 women with ER-negative disease, and an intermediate effect among 4800 women with unknown ER status. Among all 12 894 women, mortality without recurrence from causes other than breast cancer was little affected (688 deaths without recurrence in 6454 women allocated to continue versus 679 deaths in 6440 controls; RR 0·99 [0·89–1·10]; p=0·78). For the incidence (hospitalisation or death) rates of specific diseases, RRs were as follows: pulmonary embolus 1·87 (95% CI 1·13–3·07, p=0·01 [including 0·2% mortality in both treatment groups]), stroke 1·06 (0·83–1·36), ischaemic heart disease 0·75 (0·60–0·95, p=0·02), and endometrial cancer 1·74 (1·30–2·34, p=0·0002). The cumulative risk of endometrial cancer during years 5–14 was 3·1% (mortality 0·4%) for women allocated to continue versus 1·6% (mortality 0·2%) for controls (absolute mortality increase 0·2%). For women with ER-positive disease, continuing tamoxifen to 10 years rather than stopping at 5 years produces a further reduction in recurrence and mortality, particularly after year 10. These results, taken together with results from previous trials of 5 years of tamoxifen treatment versus none, suggest that 10 years of tamoxifen treatment can approximately halve breast cancer mortality during the second decade after diagnosis." @default.
• W2161977537 created "2016-06-24" @default.
• W2161977537 creator A5000705184 @default.
• W2161977537 creator A5005887947 @default.
• W2161977537 creator A5005904895 @default.
• W2161977537 creator A5006129657 @default.
• W2161977537 creator A5010127891 @default.
• W2161977537 creator A5013475678 @default.
• W2161977537 creator A5014434734 @default.
• W2161977537 creator A5014491534 @default.
• W2161977537 creator A5024973148 @default.
• W2161977537 creator A5029564842 @default.
• W2161977537 creator A5032307345 @default.
• W2161977537 creator A5033653230 @default.
• W2161977537 creator A5034206422 @default.
• W2161977537 creator A5035891540 @default.
• W2161977537 creator A5037204756 @default.
• W2161977537 creator A5039316545 @default.
• W2161977537 creator A5041214836 @default.
• W2161977537 creator A5041941850 @default.
• W2161977537 creator A5048777835 @default.
• W2161977537 creator A5054677442 @default.
• W2161977537 creator A5055063301 @default.
• W2161977537 creator A5055124181 @default.
• W2161977537 creator A5059420678 @default.
• W2161977537 creator A5060741793 @default.
• W2161977537 creator A5061419027 @default.
• W2161977537 creator A5061631163 @default.
• W2161977537 creator A5067497872 @default.
• W2161977537 creator A5068132774 @default.
• W2161977537 creator A5070889333 @default.
• W2161977537 creator A5070904518 @default.
• W2161977537 creator A5071392988 @default.
• W2161977537 creator A5072952828 @default.
• W2161977537 creator A5075495847 @default.
• W2161977537 creator A5076494866 @default.
• W2161977537 creator A5077865378 @default.
• W2161977537 creator A5085243640 @default.
• W2161977537 creator A5086477050 @default.
• W2161977537 creator A5090621185 @default.
• W2161977537 date "2013-03-01" @default.
• W2161977537 modified "2023-10-16" @default.
• W2161977537 title "Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial" @default.
• W2161977537 cites W1961026612 @default.
• W2161977537 cites W1980557732 @default.
• W2161977537 cites W1987982328 @default.
• W2161977537 cites W1992095316 @default.
• W2161977537 cites W2004975981 @default.
• W2161977537 cites W2015473392 @default.
• W2161977537 cites W2018815919 @default.
• W2161977537 cites W2028528503 @default.
• W2161977537 cites W2098529121 @default.
• W2161977537 cites W2118728607 @default.
• W2161977537 cites W2133184701 @default.
• W2161977537 cites W2147026385 @default.
• W2161977537 cites W2166631738 @default.
• W2161977537 cites W2166969772 @default.
• W2161977537 cites W2171538830 @default.
• W2161977537 cites W2258079619 @default.
• W2161977537 cites W3026080225 @default.
• W2161977537 doi "https://doi.org/10.1016/s0140-6736(12)61963-1" @default.
• W2161977537 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3596060" @default.
• W2161977537 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23219286" @default.
• W2161977537 hasPublicationYear "2013" @default.
• W2161977537 type Work @default.
• W2161977537 sameAs 2161977537 @default.
• W2161977537 citedByCount "1567" @default.
• W2161977537 countsByYear W21619775372012 @default.
• W2161977537 countsByYear W21619775372013 @default.
• W2161977537 countsByYear W21619775372014 @default.
• W2161977537 countsByYear W21619775372015 @default.
• W2161977537 countsByYear W21619775372016 @default.
• W2161977537 countsByYear W21619775372017 @default.
• W2161977537 countsByYear W21619775372018 @default.
• W2161977537 countsByYear W21619775372019 @default.
• W2161977537 countsByYear W21619775372020 @default.
• W2161977537 countsByYear W21619775372021 @default.
• W2161977537 countsByYear W21619775372022 @default.
• W2161977537 countsByYear W21619775372023 @default.
• W2161977537 crossrefType "journal-article" @default.
• W2161977537 hasAuthorship W2161977537A5000705184 @default.
• W2161977537 hasAuthorship W2161977537A5005887947 @default.
• W2161977537 hasAuthorship W2161977537A5005904895 @default.
• W2161977537 hasAuthorship W2161977537A5006129657 @default.
• W2161977537 hasAuthorship W2161977537A5010127891 @default.
• W2161977537 hasAuthorship W2161977537A5013475678 @default.
• W2161977537 hasAuthorship W2161977537A5014434734 @default.
• W2161977537 hasAuthorship W2161977537A5014491534 @default.
• W2161977537 hasAuthorship W2161977537A5024973148 @default.
• W2161977537 hasAuthorship W2161977537A5029564842 @default.
• W2161977537 hasAuthorship W2161977537A5032307345 @default.
• W2161977537 hasAuthorship W2161977537A5033653230 @default.
• W2161977537 hasAuthorship W2161977537A5034206422 @default.
• W2161977537 hasAuthorship W2161977537A5035891540 @default.
• W2161977537 hasAuthorship W2161977537A5037204756 @default.
• W2161977537 hasAuthorship W2161977537A5039316545 @default.
• W2161977537 hasAuthorship W2161977537A5041214836 @default.
• W2161977537 hasAuthorship W2161977537A5041941850 @default.

• next